Clarius Prostate AI reduces prostate volume measurement time from minutes to seconds, enhancing clinical efficiency. The application integrates with Clarius handheld ultrasound scanners and calculates ...

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s ...

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP. When communicating her patients, Anna Myers, CNP, places great ...

The RAPID III trial evaluates the FloStent System, a minimally invasive implant for BPH-related LUTS, enrolling 215 patients across the US and Australia. FloStent offers a non-surgical, reversible ...

The ARID II trial evaluates the Voro Urologic Scaffold for post-prostatectomy stress urinary incontinence, enrolling 266 patients across 30 US sites. The Voro Urologic Scaffold is designed to support ...

A recent study in JCO Oncology Practice found that in the oncology medical literature, women had a 15% lower Altmetric Attention Score (AAS) as first authors, and an 8% lower (AAS) in the last author ...

The Break Wave System offers a noninvasive, anesthesia-free option for kidney stone treatment using low-pressure ultrasound waves. The SOUND trial enrolled 64 patients to assess the system's safety ...

Low baseline IsoPSA index correlates with reduced risk of clinically significant prostate cancer in patients with elevated PSA levels. Patients with low IsoPSA index showed lower rates of prostate ...

Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial. The FDA approved ...

The AUA Annual Meeting will cover bladder cancer, prostate cancer, sexual health, and BPH, featuring practice-changing sessions and clinical trials. Interviews with experts will discuss new guidelines ...

Testicular cancer cure rates have improved, but challenges in recurrence prediction and quality of life management persist. Emerging biomarkers, such as miR-371a-3p, show promise in improving ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...